Jci_page_head_homepage_01 Jci_page_head_homepage_02
Eddy S. Yang, Hong Wang, Guochun Jiang, Somaira Nowsheen, Allie Fu, Dennis E. Hallahan, Fen Xia
Published in Volume 119, Issue 5
J Clin Invest. 2009; 119(5):1124–1135 doi:10.1172/JCI34051
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 8
Lithium-mediated effects are not apparent in glioma tumor cells.

Cells of the glioma cancer cell line GL261 were treated with 3 mM lithium for 7 days. Following the treatment period, cells were exposed to 3 Gy. At the indicated times after IR, cells were processed for immunofluorescence staining for γ-H2AX (A), DNA-PK T2609 (B), or Rad51 (C). Data (mean ± SEM from 3 independent experiments) show the percentage of cells containing greater than 10 foci. Experiments were performed simultaneously with HT-22 cells (γ-H2AX, Figure 2A; T2609, Figure 3A; Rad51, Figure 5A). (D and E) Neuroprotection by lithium is not evident in glioma tumor cells and is unaffected by the addition of the DNA-PK inhibitor IC86621. Cells of the glioma cancer cell line GL261 were treated with 3 mM lithium for 7 days. At 24 hours before IR, cells were exposed to the DNA-PK inhibitor IC86621 for 24 hours and subsequently irradiated with 3 Gy. At the indicated times after IR, cells were processed for immunofluorescence staining with DAPI and cleaved caspase-3, indicative of apoptosis activation. Data (mean ± SEM from 3 independent experiments) show percentage of cells with positive cleaved caspase-3 staining and pyknotic or condensed nuclei after subtracting respective basal apoptotic levels from each condition.